A Massachusetts biotech called Apnimed is pushing a once-daily pill, AD109, through late-stage trials as a potential first oral treatment for obstructive sleep apnea, aiming to help people who struggle with CPAP masks. Clinical results report big reductions in nightly breathing interruptions and better oxygenation, with common side effects that appear manageable. The company plans a new drug application to the FDA in the first half of 2026, targeting possible availability in 2027 if regulators agree.
Obstructive sleep apnea, or OSA, affects millions in the U.S. and around the world, and it shows up as repeated pauses in breathing during sleep. Those pauses fracture sleep and leave people feeling constantly tired, which can ripple into work, mood and safety. A different condition, central sleep apnea, involves the brain failing to signal breathing properly, but OSA stems from a physical collapse of the upper airway during sleep.
“The intermittent stopping of breathing leads to brief awakenings in people who suffer from OSA,” sleep expert Paul Muchowski, Ph.D., founder and CEO of Defined Sleep in San Francisco, told Fox News Digital. “These awakenings disrupt the normal architecture of sleep, ultimately leading to a decrease in deep, restorative sleep.”
People with OSA commonly wake unrefreshed and report fatigue, irritability, trouble concentrating and morning headaches. Over time, untreated OSA raises the risk for heart problems, stroke and neurodegenerative conditions like Alzheimer’s and Parkinson’s. Because symptoms can sneak up slowly, many sufferers and their partners miss the signs until a sleep study nails the diagnosis.
Diagnosis typically comes from a sleep study where sensors monitor heart, lung and brain activity to map breathing events and sleep stages. The standard first-line therapy is a CPAP machine that keeps the airway open with pressurized air delivered through a mask. That approach is effective for many, but widespread nonadherence is real—masks can be uncomfortable, noisy or simply inconvenient for regular use.
There are other paths too: weight loss can reduce severity, and in select cases surgery may be appropriate to remove obstructions like enlarged tonsils. In 2024 the FDA approved a weight-loss drug for adults with obesity as a route to treat moderate-to-severe OSA in a limited population, but that strategy addresses weight rather than the core airway-control problem. For patients who cannot tolerate CPAP or who need alternatives, a targeted medication would be a game changer.
Apnimed’s AD109 is designed to do just that by acting on the neural control of throat muscles during sleep, helping keep the airway more open. The pill combines aroxybutynin, which helps control muscle signaling, and atomoxetine, which raises norepinephrine levels to boost upper-airway stability. Together these two drugs aim to work synergistically to improve breathing and oxygenation through the night.
Phase 3 trials showed meaningful benefits: one study reported a 55.6% average drop in nightly apnea events after 26 weeks, along with improvements in oxygenation, and a second phase 3 trial produced similar results. The most common side effects were dry mouth and insomnia, and the company says there were no serious adverse events tied to AD109 in these trials. “Additional safety details will be included in future peer-reviewed publications,” they added.
Experts who reviewed the data call the research solid and see potential for tens of millions of people to gain better sleep and avoid OSA-related harms if AD109 wins approval. Apnimed plans to submit a new drug application to the FDA in the first half of 2026, and a standard review could take around 10 months. “Our focus right now is on completing that process rigorously and responsibly,” the company said.
